PXS
Click for more information
0.00% 8.5¢ pharmaxis ltd

Ann: Pharmaxis Acquires Control, Increases Stake in LOXL2 Program, page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
  1. newB
    3,534 Posts.
    lightbulb Created with Sketch. 64
    clock Created with Sketch.
    24/12/17
    09:43
    Post #: 29857826
    1. Interest of LOXL2 from Pharmas are intensified.
    2. Synairgen has near-term cash problem, and happy to sacrifice long term potential in LOXL2 for badly needed cash, which PXS happen to have in the bank.

    Early-mid 2018 will be interesting for PXS, when multiple trails approaching the results.
    Last edited by newB: 24/12/17
    PXS Price at posting: 25.5¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 3  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 
watchlist Created with Sketch. Add PXS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.